Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

M. P. Goetz, N. A. Bagegni, G. Batist, A. Brufsky, M. A. Cristofanilli, S. Damodaran, B. R. Daniel, G. F. Fleming, W. J. Gradishar, S. L. Graff, M. T. Grosse Perdekamp, E. Hamilton, S. Lavasani, A. Moreno-Aspitia, T. O'Connor, T. J. Pluard, H. S. Rugo, S. L. Sammons, L. S. Schwartzberg, D. G. StoverG. A. Vidal, G. Wang, E. Warner, R. Yerushalmi, P. V. Plourde, D. J. Portman, E. N. Gal-Yam

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences